Salt Lake City, Utah – December 11, 2019 – Co-Diagnostics, Inc. (Nasdaq: CODX), was recently featured in an article on genomeweb.com titled “Co-Diagnostics Continues Global Expansion With Africa Alliance, New India Facility.”
In addition to other recent news including expansion into Africa, the article discussed the regulatory clearance received last week from the Indian Central Drug Standard Control Organization for five diagnostic tests through its joint venture, CoSara Diagnostics. The clearance also enables the tests — for detecting tuberculosis, malaria, hepatitis B and hepatitis C viruses, and human papillomavirus — to be manufactured and sold from the CoSara facility in Ranoli, India.
A PDF download of the article may be found here.
About Co-Diagnostics, Inc.:
Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that develops, manufactures and markets a new, state-of-the-art diagnostics technology. The Company’s technology is utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests to locate genetic markers for use in industries other than infectious disease and license the use of those tests to specific customers.
The content included in this post may contain forward-looking statements. Forward-looking statements can be identified by words such as “believes,” “expects,” “estimates,” “intends,” “may,” “plans,” “will” and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions. Actual results may differ materially from those contemplated or anticipated by such forward-looking statements. Readers of this press release are cautioned not to place undue reliance on any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.
Co-Diagnostics Investor Relations